Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2008

View Archived Issues

ASIC1a a potential target for reducing seizures

Snapshots of alogliptin studies

TRU-015 shows good pharmacokinetic profile and safety in rheumatoid arthritis patients

Celera completes separation from Applera

CoLucid closes series B financing to fund development of COL-144

FDA approves Promus everolimus-eluting coronary stent system

Recent Boehringer Ingelheim and University of Minnesota patents report novel anti-HIV agents

Phase II trial for Fibrin Pad in surgery with severe bleeding begins

Sinovac begins enrollment in phase II study of pandemic H5N1 influenza vaccine

TAP merges with Takeda

CHMP requests additional data analyses from phase III INT-0133 trial of IDM's mifamurtide

SuperGen comments on results from phase III trial comparing Dacogen to BSC in MDS

Sciele enters agreement with Addrenex to develop and market ADX-415 for hypertension

Recent patents cover novel anticancer agents

United Therapeutics submits NDA to FDA for inhaled formulation of treprostinil for PAH

CHMP adopts negative opinion for Howmedica's Opgenra

New therapeutic options for cardiovascular disorders claimed in recent patents

XL-228 well tolerated in drug-resistant Philadelphia chromosome-positive leukemias

VG-101 gel, safe and effective in mouse model of vaginal atrophy

Taisho enters basic business alliance agreement with Biofermin

Spheramine fails to meet endpoints in phase IIb STEPS trial in PD

AstraZeneca and Palatin amend January 2007 collaboration agreement in obesity

Elixir enters license agreement with Boston University for SIRT1 modulators

Bavituximab achieves primary endpoint in ongoing phase II breast cancer trial

OncoGenex to independently develop lead cancer drug OGX-011

Favorable cardiovascular safety study results reported for ARYx's ATI-7505

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 9, 2025.
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
Omada, Caris arrivals continue med-tech IPO hot streak
BioWorld MedTech
Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...